GenesisCare administers novel diagnostic agent Pylarify to first US patient

This video features commentary from Leonard Bitterman, the first patient in the United States to receive Pylarify (piflufolastat F 18), a novel radioactive diagnostic agent indicated for PSMA-PET imaging of lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy and men with suspected recurrence based on an elevated PSA level. Brief commentary is also provided by Kishore K. Dass, MD, a radiation oncologist at GenesisCare in Boca Raton, Florida, where Bitterman received the treatment.